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Objectives. The goal of this review is to reevaluate the unstable
coronary syndromes in the setting of new therapies and biochem-
ical markers.
Background. Patients with acute coronary syndromes comprise
a large subset of many cardiology practices. Patients with unsta-
ble angina (UA) and non-Q wave myocardial infarction (NQMI)
may sustain a small amount of myocardial loss but have signifi-
cant amounts of viable, yet ischemic, myocardium, placing them at
high risk for future cardiac events. In the past, enzyme differen-
tiation of NQMI from UA was considered important to assess
prognosis and direct therapy.
Methods. Manuscripts published in peer-reviewed journals
over the past three decades were reviewed and selected for this
review. Recent abstracts were also considered and cited where
appropriate.
Results. In the late 1990’s, although UA and NQMI remain
parts of a spectrum, it is apparent that the distinction between
these two entities is no longer sufficient to identify high risk
patients; rather, specific electrocardiographic changes, aspects of
the clinical history, newer biochemical markers, and angiographic
findings help to better distinguish higher risk individuals from a
large patient population with unstable coronary syndromes and
these factors usually determine therapy.
Conclusions. Based on these results, it is likely that newer
therapies such as glycoprotein IIb/IIIa receptor antagonists, low
molecular weight heparins, and coronary stents will be directed
toward these high risk patients.
(J Am Coll Cardiol 1999;33:107–18)
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Unstable angina (UA), non-Q wave myocardial infarction
(NQMI), and Q wave myocardial infarction (QMI) constitute
the diagnoses collectively termed “the acute coronary syn-
dromes” (1,2). All are related pathogenetically, as each repre-
sents different stages of plaque rupture and thrombosis. With
UA, no myocardial necrosis occurs; the distinction between
QMI and NQMI resides in the development of electrocardio-
graphic Q waves (3,4), although there are short and long term
clinical implications as well.
Until recently, distinguishing among these three acute
entities has been a central diagnostic goal because of the
apparent therapeutic implications based on clinical trials. For
example, beta-adrenergic blocking agents are effective in UA
(5) and QMI (6), but not in NQMI; conversely, diltiazem is
advised for NQMI without heart failure (7), and calcium
antagonists generally are useful in UA (5) but not in QMI (8).
However, there are so many pathogenetic similarities among
these syndromes (such as the presence of ischemic but viable
myocardium to be salvaged and the presence of thrombus) that
the logic behind these differences in therapeutic strategies is
elusive. Furthermore, as newer diagnostic serum markers have
become available, the irreversible death of myocytes seems a
less than distinctive characteristic upon which to rest manage-
ment. In addition, new antiplatelet agents and interventional
devices have recently made distinguishing between NQMI and
UA less relevant in clinical practice than it has previously been.
Rather, it appears that certain specific features of patients with
acute coronary syndromes, such as the presence of ST segment
elevation or depression on the admission electrocardiogram or
the angiographic presence of complex lesions with thrombus,
now are the crucial features most directly influencing prognosis
and directing therapy.
This review is a reexamination of the pathophysiology,
clinical diagnosis, and treatment strategies of acute coronary
syndromes in view of these new developments. A critical
reevaluation of clinical trial data and recent developments in
diagnostic techniques suggest that a distinction between
NQMI and UA based on enzyme markers, while of interest
categorically, is no longer sufficient to assess prognosis or
direct therapy.
Pathophysiology of Unstable
Ischemic Syndromes
Unstable angina (UA). Pathoanatomy. The inciting event
underlying the development of all acute ischemic syndromes is
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rupture of an atherosclerotic plaque in a coronary artery (9).
The lipid core of a plaque is composed of oxidized LDL
cholesterol and macrophages and is separated from the vascu-
lar lumen by a fibrous cap. The thinnest part of the cap lies at
its junction with normal endothelium along the edges of the
cap. The combination of enzyme degradation and external
mechanical shear forces in the artery results in rupture of the
fibrous cap and exposure of the underlying highly procoagulant
atheromatous material to the bloodstream. Macrophage dep-
osition and infiltration ensues with release of enzymes, result-
ing in digestion of the fibrous cap’s collagen and elastin (10).
Recent evidence suggests that cytokines released from inflam-
matory cells within the cap at the attachment to the atheroma
enhance the process of plaque destabilization by inhibiting
collagen synthesis. The mechanical force of systole acts at the
edges of the fibrous cap, which are locations of high circum-
ferential stress, to cause further plaque breakdown. Other
factors such as hypertension, smoking, catecholamine release,
and vasospasm also predispose to plaque rupture (1,2).
The ruptured plaque is irregular in shape with an exposed
underlying surface that favors thrombus formation, the second
step in development of an unstable ischemic syndrome (11). A
dynamic process produces simultaneous thrombosis and
thrombolysis locally, with the resultant equilibrium between
the two determining the particular ischemic syndrome (12).
Platelets deposit initially but the platelet clump may not stay
apposed to the disfigured plaque unless stabilized by fibrin.
Secretion of thromboxanes, serotonin, and other vasoactive
substances promote further platelet aggregation (13–15). The
reduction in blood flow and the irregular surface of the platelet
aggregate enhance the buildup of thrombus by way of throm-
boxane B2, and release of leukotrienes from leukocytes. Va-
sospasm likely also contributes both to plaque rupture and
thrombus formation (16).
Recent studies have shown that in UA, plaque morphology
may correlate directly with clinical presentation. Increasing
severity of UA by Braunwald classification has been associated
with increasing prevalence of thrombus, cellularity, atheroma,
and neovasculature in plaque fragments obtained from direc-
tional atherectomy (17). Plaque fragments from patients with
stable angina are mainly fibrous in composition and are
without the complexity noted with UA. These findings further
support a pathoanatomic distinction between UA and stable
angina.
Coronary angiographic findings. The angiographic ap-
pearance of a ruptured plaque with superimposed thrombus is
one of a “complex” lesion. Ambrose et al. referred to these as
“eccentric type II” lesions consisting of asymmetric, convex
obstructions with a narrow neck, containing scalloped or
overhanging edges (18,19). They are now characterized as
complex or complicated lesions (20). The associated thrombus
is suggested by a hazy filling defect on contrast arteriography.
These lesions are seen in more than 70% of patients with
unstable coronary syndromes and in only 10–20% of patients
with stable syndromes (21). By use of intravascular ultrasound,
it has been estimated that angiography may not detect as many
as 50% of thrombi when present (21). Similar to pathoana-
tomic findings, the angiographic results of patients with UA
may vary depending on the specific clinical presentation.
In UA, the complex plaque usually progresses over several
weeks, in contrast to NQMI in which complex plaques actually
appear more simple on restudy, probably after thrombolysis
(22). The majority of coronary stenoses are initially less than
70% in UA patients (23). The presence of associated thrombus
depends on the specific clinical presentation and the timing of
coronary angiography in relation to presentation and initiation
of medical therapy. Some studies have determined that a
shorter duration of pain free interval (,1 hour) and a longer
duration of pain (.15 minutes) correlate well with lesion
complexity and in-hospital events (24,25).
A recent prospective study of 284 patients with UA under-
going cardiac catheterization has correlated clinical presenta-
tion with angiographic findings (26). New onset rest angina had
the highest association with complex lesions, intracoronary
thrombus, and total occlusion. Postinfarction angina was
strongly associated with intracoronary thrombus, complex le-
sions, and reduced TIMI flow compared with other Braunwald
subgroups. In a separate analysis, the Braunwald classes were
found to be independent correlates of angiographic morphol-
ogy; that is, Class III (recent onset rest angina) was an
independent correlate of complex lesions, total occlusions, and
TIMI flow grade ,3. Postinfarction angina correlated with
intracoronary thrombus, total occlusions, and TIMI flow grade
,3. This study resulted in data linking clinical presentation
and complex coronary anatomy in patients with unstable
coronary syndromes.
Coronary angioscopic findings. Unstable plaque appears
yellow and friable compared to the smooth, white surface of
stable plaques (27). There are also dark, purple areas of
subintimal hemorrhage. In patients with UA, the overlying
thrombus appears white in contrast to the red thrombi in acute
myocardial infarction. The white color is primarily due to
platelet clumps and the red color is due to an accumulation of
red blood cells (10,28).
However, a recent histopathophysiologic study examining
pathologic specimens of culprit lesions in UA, MI, and stable
angina obtained by directional coronary atherectomy noted
little difference in plaque morphology in UA and NQMI (29).
Abbreviations and Acronyms
CHF 5 congestive heart failure
CAD 5 coronary artery disease
CI 5 coronary intervention
CPK 5 creatinine phosphokinase
ECG 5 electrocardiogram
GP 5 glycoprotein
LMWH 5 low molecular weight heparin
NQMI 5 non-Q wave myocardial infarction
QMI 5 Q wave myocardial infarction
UA 5 unstable angina
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Plaques from both contained platelets and red thrombus,
perhaps explaining why heparin and the new antiplatelet
agents are equally effective in both patient groups. Thrombol-
ysis tends to predominate in UA and clotting predominates in
NQMI patients (20). This is important evidence that UA and
NQMI are not pathophysiologically distinct entities but rather
exhibit overlapping features.
Non Q-wave myocardial infarction (NQMI). Patho-
anatomy. Rupture of an atheromatous plaque is the initial
step in the development of NQMI as it is in UA. Non-Q wave
myocardial infarction often occurs after a rapid progression of
atherosclerotic lesions at a site which was recently minimally
diseased or as transient occlusion at the site of severe stenosis
in the presence of extensive collateral circulation (21). Fuster
et al. proposed the following explanation for differences be-
tween NQMI and UA (1,2): in UA, mild plaque injury allows
for formation of a labile thrombus which occludes the artery
for 10 to 20 min. Superimposed vasoconstriction, probably
secondary to endothelial dysfunction, further assists in vessel
occlusion. In NQMI, the duration of occlusion is longer, likely
due to a higher degree of plaque damage than in the UA
setting, resulting in CPK leakage from the myocardium.
Reperfusion usually occurs within two hours preventing QMI,
as in 75% of patients with NQMI, the infarct related artery is
patent with an extensive collateral circulation.
Coronary angiographic findings. DeWood et al. per-
formed early studies examining angiographic findings in
NQMI (30). Using serial angiography, they observed that as
few as 25% of NQMI patients had total occlusions in the first
24 h and 85% of these patients had collaterals to the occluded
segment. Others have found that many of the coronary arterial
segments that later become the site of NQMI have either
minimal plaques with little or no angiographic evidence of
atherosclerotic disease or else contain severe stenoses of
variable angiographic morphology (31).
Some subtle distinctions differentiate NQMI from UA
angiographically. The presence of total occlusion is approxi-
mately 20–40% in NQMI and less in UA, averaging 10–20%
(30). In either case, though, complete occlusion may be
followed by recanalization. Further, thrombi and multiple
filling defects are more likely to be present in NQMI than in
UA; however, the timing of angiography in relation to presen-
tation in UA may determine identification of thrombus (20). It
appears that the complexity of lesions in UA on serial angiog-
raphy actually progresses with time, while in NQMI complex-
appearing lesions actually resolve over the course of two to
three months (22). Ulcerated plaques with overhanging edges
seen more commonly in UA may become more obvious in
NQMI patients after gradual thrombolysis (32,33).
Clinical Presentations
The clinical presentations of patients with unstable syn-
dromes encompass a wide spectrum. For example, UA patients
may present with new onset angina, a changing pattern of
angina, angina at rest or with decreasing workloads, and
postinfarction angina. Each of these patterns likely represents
different pathoanatomic stages. The electrocardiographic find-
ings vary from being entirely normal to demonstrating signifi-
cant ST segment depression, ST segment elevation, or T wave
abnormality.
Myocardial infarction is primarily distinguished from UA
by the presence of CPK-MB enzyme elevation, but serum
markers are not evident until several hours after presentation.
History, physical examination, and initial ECG are unable to
allow, in many cases, the clinician to make a distinction with
confidence. Because of this consideration, a recent study from
the TIMI III trial examined 50 clinical and electrocardio-
graphic variables as predictors of development of NQMI in
those presenting with anginal symptoms and ECG changes
(34). Four factors were predictive, including: 1) the absence of
prior PTCA, 2) duration of pain more than 60 minutes, 3) ST
segment deviation on the qualifying ECG, and 4) recent onset
of angina. Approximately 50% of patients who had three of
four characteristics had a NQMI and 70% of patients with four
characteristics had a NQMI. Thus, even when three of four
distinguishing characteristics are present, there is still a 50%
chance of misclassification as UA or NQMI.
In current practice, the earliest objective features of pa-
tients with suspected acute coronary syndromes are the pre-
senting electrocardiographic changes. Many patients present-
ing with NQMI may have ST segment elevation but more
commonly will have ST segment depression and/or associated
T wave inversions. UA may similarly present with ST segment
elevation. Although not as common as with QMI and NQMI,
ST segment elevation has been reported in as many as 16% of
UA patients in one series (35). Combinations of ST segment
elevation and depression or ST segment depression alone may
occur. Therefore, ST segment shifts are not specific to any of
the three coronary syndromes. The further development of Q
waves is not predictable, so the most significant early distinc-
tion lies in evaluation of the ST segments and T waves. The
significance of this differentiation is that thrombolytic therapy
has been shown to be of benefit in patients with ST segment
elevation but not in those with ST segment depression or
isolated T wave changes (36).
Risk Stratification and Prognosis—the
Clinical History and Initial
Electrocardiogram (Table 1)
In both UA and NQMI, the most important adverse
electrocardiographic prognostic indicator is the presence of ST
segment depression. Several studies have shown that the most
significant indicator of future clinical events including recur-
rent angina, reinfarction, or death is the presence of ST
segment depression (37). In a recent study by Nyman et al.
evaluating the ECGs of 911 men with UA or NQMI admitted
to the CCU, patients were followed for the endpoints of
cardiac death, myocardial infarction, or severe angina for up to
one year (38). Those patients with admission ST depression on
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the ECG were at highest risk (18%) of future MI or recurrent
angina. Of note, cardiac enzyme levels did not predict out of
hospital cardiac events nor did location of ECG changes. In
another study evaluating subgroups of patients with NQMI, ST
segment depression was associated with lower LV ejection
fraction, more hospital complications, and a higher mortality
rate at one year than ST segment elevation (39). It appears that
persistent ST depression places the patient at very high risk.
Schechtman et al. found a one year mortality rate of 22.2%
when ST segment depression persisted after hospital discharge
(40). Further, the location of changes, particularly leads V1–
V4, suggests a large area of myocardium at increased risk of
adverse events independent of CPK level at presentation.
The ECG provides easily obtainable prognostic informa-
tion, but it is well known that the extent of coronary artery
disease (CAD) and resting ejection fraction in UA patients
also contribute. Certainly, severe three vessel CAD or signifi-
cant stenosis in the left main coronary artery or left anterior
descending artery may result in at least a twofold higher
mortality rate than disease in the right coronary artery and/or
left circumflex coronary artery (41). Similarly, patients present-
ing with pulmonary edema in UA have a high incidence of
severe CAD and a poor prognosis, which is dramatically
lessened by revascularization procedures (42). In general,
coronary bypass grafting can be performed with low perioper-
ative mortality in patients with UA and markedly depressed
left ventricular function (43).
In an effort to assess other clinical factors and risk stratify a
very heterogeneous UA group, Braunwald proposed a classi-
fication system in 1989 based on the severity of symptoms and
clinical circumstances at the time of presentation (44). A
prospective validation of this system was performed in a cohort
of 393 consecutive patients with UA (45). Five variables-postin-
farction angina, the need for intravenous nitroglycerin on
admission, the absence of beta-blocker or rate-lowering cal-
cium channel blocker prior to admission, and baseline ST
segment depression-were predictive of major in-hospital com-
plication. In addition, increasing age and coexistent diabetes
were also predictive. A subsequent prospective study in 417
consecutive patients with the diagnosis of UA in regard to six
month outcome similarly found that postinfarction angina and
intravenous nitroglycerin therapy were the most predictive of
adverse outcome along with advanced age and presence of
ECG changes on admission (46).
There are specific features of NQMI as well which are
predictive of adverse outcome. Posthospital reinfarction and
recurrent angina are higher in NQMI than QMI, offsetting the
higher early risk with QMI. Anterior location, persistent ST
segment depression, and associated congestive heart failure
(CHF) are independent predictors of increased early mortality
in NQMI patients up to three months post event (47). Late
mortality is higher in older patients, those with diabetes, and
those suffering reinfarction (48). As with UA, the presence of
ischemic, yet viable, myocardium suggested by recurrent an-
gina or reinfarction portends higher risk. However, the occur-
rence of NQMI also indicates myocardial necrosis, and so
anterior location and history of CHF likely also predispose to
increased likelihood of life-threatening arrhythmias and sud-
den cardiac death.
The Contribution of Biochemical Markers to
Prognosis and Risk Stratification
A number of biochemical markers have been studied in the
setting of ischemic syndromes. The primary focus of the past
three decades has been to identify cellular markers that
reliably and rapidly diagnose myocardial injury to provide
more rapid treatment for a higher risk subset of patients.
CKMB levels are often obtained at initial presentation of
patients with suspected ischemic syndromes and are checked
serially every 4–6 h until they reach a peak. Increases in
plasma levels occur between 6 to 10 h after the onset of
infarction but may occur sooner in NQMI or “smaller” infarc-
tions as recanalization increases the rapidity with which CKMB
appears in the plasma (49). Resolution usually occurs within 36
to 72 h but may be prolonged in patients with renal dysfunction
or hypothyroidism. While ECG changes and clinical presenta-
tion often overlap, CKMB levels are utilized to distinguish
between UA and NQMI. A prospective study performed in 199
patients with UA in which frequent CPK serum levels were
obtained showed that total CPK levels may also be elevated in
as many as 19% of patients with UA, somewhat reducing the
specificity of enzyme sampling (50). Of particular importance
was that patients with elevated CPK levels had a higher rate of
reinfarction than those without elevations. It has been gener-
ally felt, though, that elevated CKMB levels, when present,
indicate myocyte injury and reduced left ventricular dysfunc-
tion, placing the patient at higher risk for future events.
Myoglobin is a low molecular weight protein present in
cardiac and skeletal muscle that is a sensitive but not specific
marker of myocardial injury (51). It is rapidly released from
necrotic myocardium and subsequently rapidly cleared by the
Table 1. Early Indicators of High Risk Patients With Unstable
Coronary Syndromes
1. Electrocardiographic findings ST segment depression
2. Clinical presentation Braunwald Class III or C
Need for I.V. nitrates
Increased age
Diabetes mellitis
3. Biochemical markers Elevated troponin I or T
4. Echocardiographic findings Reduced left ventricular function
Anterior wall involvement
5. Angiographic findings Complex lesions
Thrombus
6. Predischarge noninvasive testing Reversible perfusion defects on nuclear
imaging
Wall motion abnormalities by
echocardiography
Increased lung/myocardial uptake on
nuclear imaging
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kidneys. The rate of rise of serum myoglobin levels is more
rapid during reperfusion of previously occluded coronary
vessels as may occur with NQMI. Elevated levels of myoglobin
are also found in patients with UA, perhaps released from
skeletal muscle in severely ill patients and may obscure differ-
entiation of UA from NQMI. Myoglobin, then, is a very
nonspecific marker in unstable ischemic syndromes.
Recently, the troponins have been studied extensively and
were approved for clinical use by the Food and Drug Admin-
istration in 1994. Troponin I, C, and T form a complex that
regulates the calcium-modulated interaction of actin and my-
osin in striated muscle (51). Monoclonal antibodies to tropo-
nin I have been developed which have no cross-reactivity with
noncardiac skeletal muscle isoforms, as may occur with tropo-
nin T. Troponin I is more specific for myocardial cell injury and
elevations do not occur in patients with skeletal muscle injury
(e.g., in the perioperative setting) or in patients with renal
failure, unless concomitant cardiac damage has occurred (52).
Given that troponins are reliable markers of myocardial cell
injury, recent studies have focused on the prognostic informa-
tion they provide. When analyzing patients presenting with
UA, the subgroup of patients with elevated troponin T levels
appears to define a group at higher risk of adverse outcome.
Specifically, in a study by Hamm et al. (53), the risk of
in-hospital MI or cardiac death among patients with UA and
normal CKMB levels was significantly higher in those with
detectable troponin T levels in the range of 0.2 to 3.64 mcg/L
despite standard medical therapy. Further, in a group of 240
patients with documented myocardial infarction (Q wave or
NQMI) by WHO criteria, Stubbs et al. (54) found that an
admission troponin T level of greater than or equal to
0.2 mcg/L, especially in association with ST segment elevation,
identified a group at high risk of MI or cardiac death within
three years.
It appears that the prognostic information provided by
these proteins is independent of the classification of the
patient’s presentation as UA or acute MI. Ohman et al. (55)
studied 855 patients in the GUSTO-IIa study group presenting
within 12 h of the onset of symptoms consistent with myocar-
dial ischemia. Approximately 1⁄3 of patients had an elevated
troponin level (.0.1 mcg/L) and mortality was significantly
higher in these patients than in patients who had lower levels
of troponin at 30 days. Troponin T level was more strongly
correlated with 30 day survival than electrocardiographic cat-
egory or CKMB level. A retrospective analysis by Antman et
al. (56) of 1404 patients in the TIMI IIIB study found that
levels of troponin I greater than 0.4 mcg/L were associated with
a significantly higher mortality within 42 days than lower levels
and that mortality increased for each 0.1 mcg/L rise in troponin
levels. Troponin I level was an independent risk factor for
death even when adjusting for baseline characteristics such as
ST depression and age, which were also predictive of mortality.
Although predictive of short term outcome, troponin T also
has long term prognostic value as studied by Lindahl et al. (57);
976 patients presenting with ischemic symptoms and/or elec-
trocardiographic changes consistent with myocardial ischemia
were followed for five months after presentation. The maxi-
mum troponin T level in the first 24 h was an independent
predictor of future MI or cardiac death in the ensuing 5
months, and increasing troponin levels were proportional to a
higher event rate. In addition, there was considerable overlap
of maximum troponin T levels in patients with MI or UA
especially in the intermediate 0.06 to 0.18 mcg/L range.
As discussed, it has been suggested that the specificity of
troponin I may be higher for myocardial tissue than troponin
T. Accordingly, Galvani et al. (58) studied 106 patients pre-
senting with chest discomfort within 48 h of admission with the
primary endpoints at 30 days and one year being death or
nonfatal MI. A troponin I level greater than 3.1 mcg/L was an
independent risk factor for death or nonfatal MI within 30 days
and the prognostic value was maintained at one year. Only
68% of patients with troponin I elevations were free of cardiac
events as compared with 90% of those without elevations.
Though higher levels of troponins seem to indicate in-
creased risk, are low levels enough to obviate further evalua-
tion and allow discharge of patients with unstable coronary
syndromes? The answer to this question is still under investi-
gation (59), although a study of 773 consecutive patients with
chest pain and without ST segment elevation on the ECG
attempted to answer this question (60). Event rates in patients
with negative troponin T or I tests were only 1.1% and 0.3%
respectively, leading the authors to conclude that negative test
results are associated with low risk and allow for safe discharge
of patients from the emergency room. More recently, however,
in a more heterogeneous cohort of more than 1,000 patients
presenting with chest pain, a negative test result (low troponin
I level) did not assure a good prognosis (61).
In summary, the current evidence shows that both troponins
T and I can be easily measured and are independent markers
of adverse outcome in both the short and long term followup
of patients with unstable ischemic syndromes. They may also
be more specific indicators than the traditional electrocardio-
graphic changes or CKMB enzyme elevations. There is early
evidence that elevated troponin levels may indicate complex
lesion morphology (62). However, further investigation is
needed to determine the appropriate treatment strategy, such
as early angiography and/or angioplasty, for patients with
elevated troponin levels and whether such intervention results
in better, more cost-effective outcomes.
The Timing of Coronary Angiography
Whether or not routine coronary angiography should be
employed in the setting of UA or NQMI has been the subject
of considerable debate in recent years. In addition, the optimal
timing of intervention has also been controversial. The belief
that patients with UA or NQMI have significant amounts of
jeopardized myocardium has pushed many cardiologists to
seek invasive evaluation early (63,64). Others have adopted a
more conservative strategy in which they have pursued angiog-
raphy only if significant ischemia is present on noninvasive
stress testing.
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Early, retrospective studies (64) suggested benefit with an
aggressive invasive approach, but large randomized studies
have shown no reduction in nonfatal reinfarction or death with
that strategy (65–67). In the recent VANQWISH study (66),
patients admitted to 15 Veterans Affairs Medical Centers from
April 1993 to December 1995 with NQMI were screened and
920 patients were actually enrolled. These patients were ran-
domized to an early invasive strategy which consisted of
coronary angiography shortly after admission followed by
angioplasty, if indicated, or an early conservative strategy with
angiography only if symptom-limited stress testing was posi-
tive. The incidence of in-hospital adverse events in the early
invasive arm was higher than in the conservative strategy as
was the average length of stay. All-cause mortality and nonfatal
reinfarction in patients randomized to the invasive arm were
significantly higher at discharge and during followup of 12 to
44 months. No subgroup of NQMI patients in the early
invasive arm appeared to benefit from that strategy and there
were no cost savings or shorter hospitalizations. Therefore, a
routine early invasive strategy may not be warranted in NQMI
as once believed, and the overall approach may not differ
significantly from that in UA where either strategy has been
followed. This should not be surprising, because most patients
with NQMI or UA have patent arteries at the time of
angiography soon after presentation, in contrast to those with
QMI, who have occluded vessels. Coronary intervention may
be more safely performed after the patient has been more
carefully evaluated and perhaps stabilized with medical ther-
apy.
Therapy (Table 2)
Antithrombotic medications. Therapy for UA and NQMI
have traditionally been similar because the initial clinical
presentations are often difficult to separate. The anticoagulant
regimen and need for interventional therapy have been studied
extensively in recent years. Aspirin and intravenous heparin
therapy are currently the mainstay of initial treatment strategy
for NQMI and UA. Theroux et al. performed a double-blind,
randomized study involving 479 patients with UA in the late
1980’s showing that either aspirin or heparin alone, or the
combination of the two, significantly reduced the incidence of MI
and refractory angina (68). However, early withdrawal of
heparin may reactivate the disease process within hours of
discontinuation; combination therapy with aspirin attenuates
this response (69).
Although numerous studies have evaluated aspirin’s efficacy
in unstable coronary syndromes, the Veterans Administration
study was the first to prospectively determine the benefit of
aspirin therapy in reduction of cardiac events in patients with
UA (70). The RISC investigators proved benefit of aspirin in
patients with either NQMI or UA (71). Subsequently, Cohen
et al. performed a multicenter investigation of antithrombotic
therapy in UA and NQMI patients admitted within 48 h of the
onset of chest pain (72). The overall ischemic event rate was
27% in both groups, but patients with NQMI had a higher
reinfarction and death rate, despite maximal antianginal and
antithrombotic medication. The addition of warfarin is not of
benefit and can only be recommended in NQMI associated
with LV thrombus. Further, the optimal duration of antithrom-
botic medication is felt to be approximately 48 h for UA and
NQMI; a more lengthy administration may result in adverse
outcome (73).
Beta blockers also appear to provide benefit in UA by
reducing myocardial oxygen demand and cardiac work to
reduce ischemia. Long term administration of beta blockers
without intrinsic sympathomimetic activity in a metaanalysis of
trials of patients with UA showed a 13% reduction in risk of
developing MI (5). Calcium channel blockers may effectively
control symptoms although there is no clear beneficial effect on
survival. Intravenous nitrates have peripheral and coronary
vascular effects, decreasing myocardial preload and left ven-
tricular end-diastolic volume. No randomized placebo con-
trolled trials have been performed in UA addressing the
efficacy of the drug for symptom relief or reduction of cardiac
events.
The focus in patients with NQMI has been on the role of
calcium channel blockers. The Diltiazem Reinfarction Study
prospectively evaluated 576 patients receiving diltiazem or
placebo beginning 24 to 72 h after NQMI and continuing for 14
days (74). There was significant reduction of reinfarction and
postinfarction angina with diltiazem. The Multicenter Dilti-
azem Post Infarction Trial (75) found a significant reduction of
adverse cardiac events in patients receiving diltiazem who did
not have pulmonary edema on presentation. Similar favorable
findings cannot be extrapolated to include other calcium
channel blockers such as verapamil and nifedipine, which have
not been found to reduce reinfarction or mortality (76–78).
Diltiazem’s unique effect on prevention of coronary vasocon-
striction and decrease in myocardial oxygen requirements by
reducing heart rate and contractility have led to its widespread
use.
The role of beta blockers in NQMI has been controversial
and routine use for NQMI cannot be advocated. Although the
Beta Blocker Heart Attack Trial (BHAT) reported significant
advantages in patients with acute MI, retrospective subgroup
analysis of NQMI patients receiving propranol after two years
Table 2. Therapeutic Options for Patients With Unstable
Coronary Syndromes
Recommendation:
Aspirin* Class I
Heparin* Class I
Nitrates* Class I
Calcium antagonists* Class I
Beta blockers* Class I
Glycoprotein IIb/IIIa antagonists† Class IIa
Coronary intervention with or without
stents‡
Class IIa
Low molecular weight heparin§ Class IIa
*: see reference 110; †: see references 85–94; ‡: see references 101–103;
§: see references 81–84.
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showed no reduction in death rates or need for revasculariza-
tion (79). These findings were criticized by some for lack of
statistical power. Another trial, though, suggested an even
higher mortality rate in NQMI patients taking metoprolol as
compared to placebo (80).
Low molecular weight heparins (LMWH) are increasingly
finding new applications in certain patients (81). The FRISC
study found a significant reduction in death and MI with
dalteparin in patients with UA already on aspirin (82). A larger
study, Fragmin in Unstable Coronary Artery Disease Study
(FRIC) randomized 1482 patients with UA or NQMI to
dalteparin or dose-adjusted unfractionated heparin for six days
in phase I and for 45 days in phase II (83). The combined
endpoint of death, myocardial infarction, recurrence of angina,
and need for revascularization procedures in both groups were
comparable, suggesting that LMWH may be an acceptable
alternative to heparin in the acute treatment of unstable
coronary syndromes. The recently published ESSENCE trial in
which over 3180 patients with UA or NQMI were randomized
to enoxaparin or standard heparin suggested an advantage of
LMWH over standard heparin (84). The data, though, are not
conclusive that LMWH should replace standard heparin, as
heparin treated patients were not always adequately anticoag-
ulated in the studies. LMWH could be administered to throm-
bocytopenic patients or those requiring long-term therapy.
Glycoprotein IIb/IIIa receptor blockers. New antiplatelet
therapies have made the distinction between NQMI and UA
less relevant from the standpoint of therapy. Activation of the
platelet glycoprotein (GP) IIb/IIIa receptor to bind fibrinogen,
fibronectin or VWF is the final step in platelet aggregation.
Several trials, complete or ongoing, have evaluated the efficacy
of new antiplatelet therapies (85–94) (Table 3). Recent trials in
acute coronary syndromes lump unstable angina with non-Q
wave MI ostensibly because these non ST segment syndromes
do not exhibit improved outcome with thrombolysis or early
intervention, and may be deleterious. Several glycoprotein
IIb/IIIa receptor blockers offer some short-term improvement,
both as stand alone therapy and in conjunction with interven-
tion at 48–72 h, but at substantial cost.
In order to evaluate fully the apparent favorable results of
the many GPIIb/IIIa antagonists, we performed a metaanalysis
to determine whether there was overall benefit of the inhibi-
tors in patients with UA and NQMI (Figure 1). There was
significant heterogeneity among the studies, (e.g., drug used,
acuity of presentation, number of patients getting interven-
tions) and so a random effects model was utilized. The
endpoint examined was the 30 day composite endpoint of
death, myocardial infarction, and recurrent ischemia with need
for repeat intervention. The number of composite endpoint
events was significantly lower for patients receiving GPIIb/IIIa
receptor antagonists compared to placebo. The relative risk of
events in patients receiving the drug was 0.79 (0.66, 0.94, 95%
confidence interval), resulting in an overall 21.3% reduction in
risk of events compared with patients receiving only aspirin
and heparin. Relative risks and 95% confidence intervals for
the 9 trials examined are shown in Fig. 1. We also examined the
effects of covariates that may affect outcome, specifically
focusing on drug type, number of patients undergoing coronary
intervention (CI), and acuity of presentation; at the p 5 0.05
level, there was no effect of these variables on overall outcome.
In summary, while still under investigation in some cases,
the GP IIb/IIIa receptor antagonists appear to be very effective
in the unstable coronary syndromes and may make the distinc-
tion between UA and NQMI less relevant. Although not
specifically compared in UA versus NQMI patients, they
reduce adverse events in patients with complex lesions with or
without CI. These agents in combination with heparin appear
to improve outcome and have an additive benefit in high risk
patients with unstable coronary syndromes although they have
not been proven long term. They may be of most benefit in
patients presenting with Braunwald class (III) or (C) UA,
when thrombus and complex lesion morphology are most likely
Figure 1. Meta Analysis of nine trials of glycoprotein IIb/IIIa antag-
onists in patients with unstable coronary syndromes. Shown are the
95% confidence intervals for the relative risk ratio of adverse events,
including myocardial infarction, recurrent ischemia, and death in
patients receiving a glycoprotein IIb/IIIa antagonist in addition to
standard therapy with aspirin and heparin. The overall relative risk
ratio was 0.79 (p 5 0.019). Solid circles 5 lower 95% C.I. for RR; open
circles 5 relative risk; solid triangles 5 upper 95% C.I. for RR.
Table 3. Studies of Glycoprotein IIb/IIIa Receptor Antagonists
Trial Acronym N Outcome
P
Value Drug
CAPTURE 1265 11.3 vs. 15.9 0.012 abciximab
PARAGON 2282 10.3 vs. 11.7 NS lamifiban
PRISM 3232 15.9 vs. 17.1 0.340 tirofiban
PURSUIT 9461 14.2 vs. 15.7 0.04 eptifibatide
EPIC* 2099 8.3 vs. 12.8 0.008 abciximab
EPILOG* 2792 5.4 vs. 11.7 ,0.001 abciximab
IMPACT II* 4010 9.2 vs. 11.4 0.063 eptifibatide
PRISM-PLUS* 1570 18.5 vs. 22.3 0.03 tirofiban
RESTORE* 2212 10.3 vs. 12.2 0.160 tirofiban
N 5 number of patients; Outcome 5 30 day composite outcome of death,
nonfatal myocardial infarction, or need for revascularization procedure in
treated patients (listed first) versus placebo patients (listed second); *Interven-
tion trials.
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present (26), as suggested by PRISM and PRISM-PLUS.
ReoPro may be used when complex anatomy is identified and
CI planned, and, if proven effective, oral GPIIb/IIIa antago-
nists could be used for medically treated patients. However,
there is no current evidence that standard heparin and aspirin
therapy should be replaced by these agents.
Thrombolytic therapy. Thrombolytic therapy is now used
frequently in the acute MI setting. Several studies have dem-
onstrated that early recanalization of the infarct related artery
will reduce infarct size and improve prognosis. Large clinical
trials have clearly established benefit in the subgroup of
patients presenting with ST segment elevation and a history
consistent with acute MI. However, patients with non ST
segment elevation presentations (UA or NQMI) appear to
derive no clinical benefit from thrombolytic therapy (95–98),
even when combined with balloon angioplasty (99).
The lack of success with thrombolysis in UA and NQMI
compared with favorable results in patients with QMI is
intriguing. While thrombolytic therapy clearly promotes clot
lysis, it also sets in motion pathophysiological mechanisms
favoring further thrombosis (100). One mechanism may be
through enhanced thrombin formation as markers of thrombin
generation such as fibrinopeptide A and thrombin; AT III
levels increase after thrombolysis. Patients with UA and high
levels of fibrinopeptide A are known to be at higher risk for
adverse events. Thrombolytic agents also activate platelets
causing release of the vasoactive substances serotonin and
thromboxane A2 which recruit other platelets and induce local
vasoconstriction. Furthermore, thrombi in patients in with UA
are composed primarily of platelets rather than erythrocytes
and are more resistant to thrombolysis than those in patients
with evolving QMI and total occlusion due to erythrocyte-rich
thrombus. Nonetheless, in NQMI or UA, thrombolytic therapy
does not provide clinical benefit for either patient subset.
Coronary interventions. The presence of thrombus and/or
complex lesions in patients with UA and NQMI have made
performing coronary interventions in these patients challeng-
ing. Although more commonly visualized in NQMI, thrombus
plays an important pathophysiologic role in UA as well, and
increases the risk of performing CI. In particular, angioscopic
features of disruption, yellow color, or thrombus at the culprit
lesion site can identify patients at high risk of early adverse
outcome after CI (1).
New devices and antiplatelet agents have been extensively
investigated to counteract these problems. Previous studies
have indicated a poorer outcome in coronary lesions contain-
ing thrombus undergoing CI. In addition to thrombotic com-
plications, a feature of high risk lesions is their tendency to
undergo abrupt closure following CI. Although stents have not
been approved for use in the setting of visible thrombus, early
results suggest that success rates with stents in thrombotic
lesions are favorable. A retrospective study of 231 patients by
Marzocchi et al. (101) compared the results of stenting in
stable and unstable angina patients and found comparable
success rates; there were high (.90%) success rates in both
groups with similar in-hospital complications, low (,2%)
subacute stent thrombosis, and low incidence of cardiac events
at six month followup. Another recent study evaluated new
devices such as autoperfusion balloons, stents, and atherec-
tomy in patients with refractory UA and achieved an 88%
success rate despite the high risk lesions (102).
These results, combined with the observations from the
TIMI IIIB investigators, suggest that the CI may be performed
safely and successfully in patients with unstable coronary
syndromes with success rates approaching those in patients
with stable plaques (103). Angiographic success was observed
in 96.1% of patients with UA or NQMI in the TIMI IIIB trial
with a low incidence of complications. While these trials did
not directly compare outcome in UA versus NQMI, it seems
that the advent of stents and glycoprotein IIB/IIIA receptor
antagonists may make it less important to distinguish between
the two as success rates in the unstable syndromes approach
those in the stable, routine CI.
Pre-discharge Diagnostic Testing
In light of the recently published VANQWISH trial (66),
predischarge stress testing plays an important role in risk
stratification and management of NQMI patients. Patients
undergoing stress testing as opposed to routine coronary
angiography had better outcomes up to 44 months out from
their events. In NQMI, predischarge symptom-limited or max-
imal exercise testing after an acute event appears to have a
higher yield than low level exercise stress testing, and can be
performed safely. Symptom limited stress testing in NQMI
patients has a greater than 75% positive predictive value for
critical stenosis of one vessel or more in the presence of 2 mm
ST segment depression. The sensitivity and specificity can be
improved with the addition of nuclear SPECT imaging (104).
Perhaps equally important is the presence of postinfarction
angina. In a study of 549 patients with acute MI (n 5 186 with
NQMI), results of exercise stress testing with or without
nuclear imaging did not impact on subsequent cardiac risk
(105). 16.7% of patients experienced a cardiac event, nonfatal
reinfarction, recurrent angina, or cardiac death in the succeed-
ing two month period. Only postinfarction angina and insulin
dependent diabetes were independent predictors of cardiac
risk.
Similarly, predischarge maximal exercise stress testing with
technetium labeled sestamibi in the absence of coronary
revascularization was assessed in 126 consecutive men with UA
stabilized with medication initially (106). Significantly, cardiac
events occurred in 39% of those with abnormal technetium
and in 60% of those with a reversible defect compared to 12%
in patients with normal scans. 2% of normals had a nonfatal
MI or cardiac death versus 25% of those with a reversible
defect. In addition, in 128 patients with UA undergoing
dipyridamole stress testing who could not exercise (predis-
charge testing), those with normal scans experienced a 10%
cardiac event rate compared with 69% of those with abnormal
results at 16 mean followup (107). Furthermore, exercise stress
echocardiography and thallium-201 SPECT imaging have been
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compared in patients one month out from an event and both
were highly sensitive (88% and 81%, respectively) for detect-
ing significant CAD with induction of wall motion abnormality
or perfusion defect (108). Long term prognostic information
can also be obtained from stress echocardiography in that 56%
of patients with a wall motion score index below the median
suffered MI or cardiac death in an eight year median followup
(109).
In summary, stress testing for patients with UA treated
medically and for patients with recent NQMI appears to be
safe and provides important prognostic information. The pres-
ence of stress induced wall motion defects with echocardiog-
raphy or a perfusion defect on nuclear imaging suggests the
presence of ischemic, yet viable, myocardium at risk. This issue
is central to the management of both NQMI and UA patients.
Current recommendations. Current recommendations for
management of patients presenting with a suspected unstable
coronary syndrome are summarized in Fig. 2. Patients who
present with chest pain (without ST segment elevation) need to
be evaluated early and risk stratified based on the clinical
history, physical examination, and presenting electrocardio-
gram. They should be risk stratified as low, medium, or high
risk as specified by Braunwald et al. (110). High risk patients
have a known history of CAD, ST segment elevation or
depression of greater than or equal to 1 mm with pain, and
hemodynamic instability. Medium risk patients include those
with T wave inversions and/or chest pain not likely to be angina
in patients with two or more cardiac risk factors. Low risk
patients include those with unlikely anginal chest pain, a
normal ECG, and one cardiac risk factor or less. Patients
considered to be at low risk may be treated with nitrates,
aspirin, and beta blockers as an outpatient. Medium and high
risk patients should be admitted and treated aggressively with
intravenous heparin, aspirin, and beta blockers. Consideration
of GPIIb/IIIa antagonists should be strong in the higher risk
groups. Cardiac catheterization should be performed early in
the high risk patients and medium risk patients with elevated
troponin levels. Medium risk patients with low troponin levels
should undergo stress testing to evaluate the extent of ischemia
before proceeding with angiography, based on evidence from
the VANQWISH study (66). Further studies are needed to
determine whether particular therapeutic interventions in re-
sponse to high risk prognostic indicators, such as troponin
elevations, are worthwhile.
We gratefully acknowledge the statistical assistance of Jill Allen, M.S. who
performed the metaanalysis of GP IIb/IIIa receptor antagonist trials.
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